BRD2 and prostate carcinoma: For example, gonadotropin-releasing hormone receptor (LHRH) agonists such as leuprolide acetate for the treatment of prostate cancer inhibit the proliferation of prostate cancer cells by down-regulating the expression of LHRH in the pituitary, inhibiting the release of follicle-stimulating hormone (FSH) and reducing the production of testosterone (Luo et al., 2023).